New CAR-T Cell Therapy Approved for Lymphoma in Spain
Madrid, March 26, 2026 – The Spanish National Health System (SNS) has incorporated a new chimeric antigen receptor (CAR-T) cell therapy for the treatment of two common subtypes of lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. This advancement aims to improve the quality of life for patients who have not responded to previous treatments or have experienced relapse.
How CAR-T Cell Therapy Works
The new treatment involves genetically modifying a patient’s own T lymphocytes – white blood cells crucial to the immune system – to express an antigen on their surface. This engineered antigen “hooks” onto tumor cells, activating the lymphocytes to target and destroy them, according to Anna Sureda, Head of the Department of Clinical Hematology at the Institut Català d’Oncologia in Barcelona .
Clinical Trial Results
Clinical trial results demonstrate promising outcomes. In patients with follicular lymphoma, a rapid and durable response was observed, with 75.7% maintaining the response at 18 months. For DLBCL, the therapy showed increased disease control compared to standard treatment approaches.
Expert Perspectives
Alejandro Martín, a researcher and hematologist at the University Health Care Complex of Salamanca, and Carlos Chaib, Medical Director of Bristol Myers Squibb in Spain and Portugal, presented the new CAR-T therapy at a press conference in Madrid. Their statements highlighted the potential of this innovative treatment to address unmet needs in lymphoma care.
Understanding Lymphoma
Non-Hodgkin lymphoma is a cancer that starts in the lymphatic system. According to data from 2018-2022, the incidence rate was 18.7 per 100,000 men and women per year in the United States . It is more common in men than women and among non-Hispanic Whites . While the 5-year relative survival rate is 74.2% , new treatments like CAR-T cell therapy offer hope for improved outcomes, particularly for those with relapsed or refractory disease.
The Role of the Sympathetic Nervous System in Chemotherapy
Recent research suggests that the sympathetic nervous system (SNS) can impact the effectiveness of cancer treatments, including chemotherapy . The SNS is a core component of solid tumors and can impair chemotherapy efficacy. Studies evaluating neural ablation have shown positive impacts on chemotherapy outcomes, suggesting that blocking neural signaling could improve treatment response .
Healthcare Expenditures and Lymphoma
Non-Hodgkin lymphoma represents a significant healthcare burden. In the United States, there are over 80,000 new cases annually, with a high survival rate, but limited national data exists regarding the associated healthcare costs .
Global Lymphoma Outcomes and Health Systems
Outcomes for lymphoma patients vary significantly worldwide, influenced by characteristics of national health systems . This highlights the importance of equitable access to advanced therapies like CAR-T cell therapy.
Worth a look